Study of Application of Pulse Electrical Stimulation Around Eye in Glaucoma Patients
- Conditions
- Glaucoma
- Interventions
- Device: Pulse Electrical Stimulation
- Registration Number
- NCT05159414
- Lead Sponsor
- Nu Eyne Co., Ltd.
- Brief Summary
This study aims to evaluate the efficacy and safety of applying pulse electrical stimulation around eyes of glaucoma patients.
- Detailed Description
Duration of study period(per participant): Screening period(0-4weeks), Intervention period(16weeks) Patient needs to visit site at least 5 times(Screening, V2, V3, V4, V5). V2 can be done with screening visit. Visit 3, 4, 5 is 2weeks, 6weeks, and 16weeks after visit 2(Baseline).
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 18
-
Participants must be 19 to 75 years of age, at the time of screening
-
Patients with normal tension glaucoma or open angle glaucoma
-
Patients with best-corrected visual acuity of 20/40 or more
-
Patients whose Mean Deviation(MD) value of visual field test is -6dB or less
-
Patients who have stable eye pressure of less than 20mmHg over the past 2 months
-
If glaucoma treatment is in progress, the type, dose, and form of drug for treatment are stable for more than 2 months
-
A person who has no pregnancy plan during the clinical trial period and has agreed to an effective contraceptive plan for WOCBP(Women of child bearing potential)
-
WONCBP(Women of non-child bearing potential) must meet at least one of the following criteria:
- Postmenopausal women who are at least 45 years old and had no menses for 24 consecutive months
- A woman who underwent hysterectomy of bilateral ovarian resection recorded by a doctor
-
All other female patients will be considered WOCBP.
-
-
A person who voluntarily agreed to participate in this clinical trial
- Ophthalmological and neurological diseases that can affect visual field test(e.g., optic neuritis, diabetic retinopathy, age-related macular degeneration, and the epiretinal membrane)
- A person with a history of surgery related to eyeball excluding simple cataract surgery or orbital surgery such as orbital fracture
- Those who have more than -6D of refractive errors
- Those who have cataracts of ETDRS(Early Treatment Diabetic Retinopathy Study) grade 3 or higher
- Those who have a history of trauma around the eyeball, such as an orbital fracture, etc.,
- Patients with active malignancy or history of malignancy, except completely treated in situ carcinoma of the cervix, completely treated and resected non-metastatic squamous of basal cell carcinoma of the skin.
- A person who recently(within 1 month before the clinical trial medical device is applied) suffered severe trauma or underwent major surgery
- Pregnant or lactating women
- Any other severe acute or chronic medical or psychological conditions
- Those who can't understand or read the consent form of this clinical trial(e.g. illiterate or foreigners)
- Any other cases that PI considers hard to participate in this clinical trial(e.g. heart-related problems, seizure, epilepsy. Patients transplanted metal or electronic device in head & neck. Patient suffering from unknown pain. Patients who are warned not to use out clinical trial device or is prohibited from using it.)
- In the case of participating in other clinical trials within 6 months prior to the time of obtaining the consent form
- Subjects who are not suitable for the clinical trial, are likely to be in danger when participate in the study or interfere with the interpretation of the trial results.
- Brain and neck implant or pacemaker including deep brain stimulation device. Implantable or wearable cardioverter defibrillator. (Dental implants are accepted.)
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Glaucoma patients Pulse Electrical Stimulation Duration of study period(per participant): Screening period(0-4weeks), Intervention period(16weeks) Patient needs to visit site at least 5 times(Screening, V2, V3, V4, V5). V2 can be done with screening visit. Visit 3, 4, 5 is 2weeks, 6weeks, and 16weeks after visit 2(Baseline).
- Primary Outcome Measures
Name Time Method Changes in intraocular pressure baseline, 2, 6, 12, 16 weeks Check the change of intraocular pressure in the baseline, 2, 6, 12, 16 weeks
Changes in pattern standard deviation(PSD) baseline, 2, 6, 12, 16 weeks Check the change of pattern standard deviation(PSD) in the baseline, 2, 6, 12, 16 weeks
Changes in visual acuity baseline, 2, 6, 12, 16 weeks Check the change of visual acuity in the baseline, 2, 6, 12, 16 weeks
Changes in mean deviation (MD) baseline, 2, 6, 12, 16 weeks Check the change of mean deviation(MD) in the baseline, 2, 6, 12, 16 weeks
Changes in visual field index(VFI) baseline, 2, 6, 12, 16 weeks Check the change of visual field index(VFI) in the baseline, 2, 6, 12, 16 weeks
- Secondary Outcome Measures
Name Time Method Changes in N95 amplitude using pattern Electroretinogram(ERG) baseline, 6, 16 weeks Check the change of N95 amplitude in the baseline, 6, 16 weeks
Changes in Glaucoma Quality of Life-15 (GQL-15) baseline, 6, 16 weeks Check the change of Glaucoma Quality of Life-15(GQL-15) score in the baseline, 6, 16 weeks
Changes in parapapillary retinal nerve fiber layer thickness (RNFLT) using optical coherence tomography(OCT) baseline, 6, 16 weeks Check the change of parapapillary retinal nerve fiber layer thickness(RNFLT) in the baseline, 6, 16 weeks
Changes in macular ganglion cell-inner plexiform layer thickness (GCIPLT) using optical coherence tomography(OCT) baseline, 6, 16 weeks Check the change of macular ganglion cell-inner plexiform layer thickness(GCIPLT) in the baseline, 6, 16 weeks
Changes in circumpapillary vessel density (cpVD) using Optical coherence tomography angiography(OCT-A) baseline, 6, 16 weeks Check the change of circumpapillary vessel density(cpVD) in the baseline, 6, 16 weeks
Changes in N95 latency using pattern Electroretinogram(ERG) baseline, 6, 16 weeks Check the change of latency in the baseline, 6, 16 weeks
Changes in macular vessel density (mVD) using Optical coherence tomography angiography(OCT-A) baseline, 6, 16 weeks Check the change of macular vessel density(mVD) in the baseline, 6, 16 weeks
Changes in Laminar cribrosa (LC) depth using optical coherence tomography(OCT) baseline, 6, 16 weeks Check the change of Laminar cribrosa(LC) depth in the baseline, 6, 16 weeks
Trial Locations
- Locations (1)
Department of Ophthalmology, Konkuk University Medical Center
🇰🇷Seoul, Korea, Republic of